A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy

PURPOSE: Combination therapy of fosaprepitant, dexamethasone (DEX) and a serotonin (5-HT(3)) receptor antagonist is a standard antiemetic prophylaxis for patients receiving highly emetogenic chemotherapy (HEC). However, the appropriate dose of DEX has not been established in Japan. This study determ...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Medicine (Baltimore)
Main Authors: Kumagai, Hozumi, Kusaba, Hitoshi, Yamanaka, Takeharu, Nio, Kenta, Inadomi, Kyoko, Takayoshi, Kotoe, Ito, Mamoru, Tamura, Shingo, Makiyama, Akitaka, Makiyama, Chinatsu, Hirano, Gen, Shibata, Yoshihiro, Shirakawa, Tsuyoshi, Mitsugi, Kenji, Ariyama, Hiroshi, Esaki, Taito, Akashi, Koichi, Baba, Eishi
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer Health 2018
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6023705/
https://ncbi.nlm.nih.gov/pubmed/29923992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000011042
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki